N-[1-(3-benzyl-4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl)propyl]-4-methylbenzamide | 1333403-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: N-[1-(3-benzyl-4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl)propyl]-4-methylbenzamide
• 英文别名: N-[1-(3-benzyl-4-oxothieno[3,2-d]pyrimidin-2-yl)propyl]-4-methylbenzamide
• CAS: 1333403-51-2
• 化学式: C₂₄H₂₃N₃O₂S
• 分子量: 417.532
• InChiKey: IOAZBLSDOVWYTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  90
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸甲酯 在 盐酸 、 4-二甲氨基吡啶 、 ammonium hydroxide 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 69.0h， 生成 N-[1-(3-benzyl-4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl)propyl]-4-methylbenzamide
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m

文献信息

• Discovery of (+)-<i>N</i>-(3-Aminopropyl)-<i>N</i>-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-<i>d</i>]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent
  作者：Maria-Elena Theoclitou、Brian Aquila、Michael H. Block、Patrick J. Brassil、Lillian Castriotta、Erin Code、Michael P. Collins、Audrey M. Davies、Tracy Deegan、Jayachandran Ezhuthachan、Sandra Filla、Ellen Freed、Haiqing Hu、Dennis Huszar、Muthusamy Jayaraman、Deborah Lawson、Paula M Lewis、Murali V. P. Nadella、Vibha Oza、Maniyan Padmanilayam、Timothy Pontz、Lucienne Ronco、Daniel Russell、David Whitston、Xiaolan Zheng

  DOI：10.1021/jm200629m

  日期：2011.10.13

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.